Dose linearity The systemic exposure of ustekinumab (Cmax and AUC) increased in an approximately dose- proportional manner after a single intravenous administration at doses ranging from 0.09 mg/ kg to 4.5 mg/ kg or following a single subcutaneous administration at doses ranging from approximately 24 mg to 240 mg in patients with psoriasis.